Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study.
Lambert AssoumouRaghiatou BaldéChristine KatlamaBaptiste AbbarPierre DelobelThierry AllegreArmelle LavoleAlain MakinsonOlivia Zaegel-FaucherLaurent GreillierCathia SoulieMarianne VeyriMathilde BertheauMichèle Algarte GeninSéverine GibowskiAnne-Geneviève MarcelinKevin BihanMarine BaronDominique CostagliolaOlivier LambotteJean-Philippe SpanoPublished in: Journal for immunotherapy of cancer (2024)
This study showed that the incidence of a first episode of grade ≥3 irAE was 15.0% (95% CI: 9.6% to 22.9%) at 1 year and the cumulative incidence of all severe irAE episodes was 26.9 per 100 person-years. Low CD4 count, positive CMV serology, history of cancer surgery and a longer time since HIV diagnosis were associated with the occurrence of severe irAEs.
Keyphrases
- papillary thyroid
- antiretroviral therapy
- squamous cell
- risk factors
- early onset
- hepatitis c virus
- human immunodeficiency virus
- risk assessment
- hiv aids
- squamous cell carcinoma
- randomized controlled trial
- coronary artery bypass
- childhood cancer
- coronary artery disease
- clinical trial
- nk cells
- surgical site infection
- placebo controlled